Liquid biopsy to identify Barrett's oesophagus, dysplasia and oesophageal adenocarcinoma: the <i>EMERALD</i> multicentre study.

ABSTRACT:

Background

There is no clinically relevant serological marker for the early detection of oesophageal adenocarcinoma (EAC) and its precursor lesion, Barrett's oesophagus (BE).

Objective

To develop and test a blood-based assay for EAC and BE.

Design

Oesophageal MicroRNAs of BaRRett, Adenocarcinoma and Dysplasia (EMERALD) was a large, international, multicentre biomarker cohort study involving 792 patient samples from 4 countries (NCT06381583) to develop and validate a circulating miRNA signature for the early detection of EAC and high-risk BE. Tissue-based miRNA sequencing and microarray datasets (n=134) were used to identify candidate miRNAs of diagnostic potential, followed by validation using 42 pairs of matched cancer and normal tissues. The usefulness of the

SUBMITTER: Miyoshi J 

PROVIDER: S-EPMC11869464 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature